Welcome to our dedicated page for Minerva Neurosci SEC filings (Ticker: NERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Minerva Neurosciences, Inc. (Nasdaq: NERV) SEC filings page on Stock Titan consolidates the company’s regulatory documents from EDGAR with AI-powered summaries to help readers interpret complex disclosures. As a clinical-stage biopharmaceutical company focused on central nervous system (CNS) diseases, Minerva uses its SEC reports to describe the status of its lead drug candidate roluperidone for negative symptoms of schizophrenia, its MIN-301 program for Parkinson’s disease, and the financial resources supporting these efforts.
In annual reports on Form 10-K and quarterly reports on Form 10-Q, Minerva provides audited and interim financial statements, research and development and general and administrative expense details, information about its liability related to the sale of future royalties, and discussion of risks associated with clinical development and regulatory review. These filings also reference the Complete Response Letter issued by the U.S. Food and Drug Administration (FDA) for the roluperidone New Drug Application and the requirement for a confirmatory Phase 3 trial.
Current reports on Form 8-K capture material events such as the October 2025 securities purchase agreement for Series A Convertible Preferred Stock and warrants, the related private placement financing of up to $200 million in gross proceeds, and the appointment of new directors and consulting arrangements tied to roluperidone’s Phase 3 program. Definitive proxy statements on Schedule 14A outline proposals for stockholder votes, including increases in authorized common stock, approval of common shares issuable upon conversion of the Series A Preferred Stock, and amendments to the company’s equity incentive plan.
On Stock Titan, each 10-K, 10-Q, 8-K, DEF 14A and related document is accompanied by AI-generated highlights that explain key points in plain language, such as how Minerva plans to use proceeds from financings, how it describes the design of its confirmatory trial, and what changes are proposed to its capital structure. Real-time updates from EDGAR and easy access to insider- and governance-related disclosures allow users to review Minerva’s regulatory history and understand how clinical, financial and corporate decisions are documented over time.
NERV submitted a Form 144 reporting a proposed resale of 650,000 shares of Common Stock. The filing also records an actual sale of 156,410 shares on 03/10/2026 for $1,191,767.01. The excerpt lists 43,274,396 shares outstanding as of 03/31/2026.
Registration covers up to $200,000,000 of securities. Minerva Neurosciences is registering an at‑the‑market shelf to offer, from time to time, up to $200,000,000 of common stock, preferred stock, debt securities and warrants, alone or in combination. The prospectus is a shelf framework; specific terms and proceeds will be set in prospectus supplements.
The filing discloses clinical plans for the lead candidate, roluperidone: a Phase 3 C19 trial expected to start in Q2 2026 enrolling 380 patients with topline efficacy in 2H 2027 and relapse data in 2H 2028. As of February 28, 2026, 43,274,398 shares of common stock were outstanding.
Minerva Neurosciences reports 2025 results and details next steps for its lead drug, roluperidone, after receiving an FDA Complete Response Letter in February 2024. The company is a clinical‑stage CNS biopharmaceutical developer focused on negative symptoms of schizophrenia.
Minerva plans a new 380‑patient Phase 3 confirmatory trial (C19) of once‑daily 64 mg roluperidone versus placebo, with first patient screening expected in the second quarter of 2026, a 12‑week primary endpoint on the PANSS Marder negative symptoms factor score, and a 40‑week relapse‑assessment phase. Topline efficacy data are expected in the second half of 2027 and relapse data in the second half of 2028.
The company recorded a 2025 net loss of $293.4 million, compared with net income of $1.4 million in 2024, and had an accumulated deficit of $688.8 million as of December 31, 2025. Minerva highlights extensive business risks, including continued losses, reliance on additional capital, and dependence on roluperidone’s clinical and regulatory success.
Minerva Neurosciences reported a large GAAP net loss of $293.4 million for 2025, driven mainly by a $321.5 million non-cash loss on the issuance of Series A convertible preferred stock and warrants, partly offset by a $45.4 million gain from the change in warrant fair value.
On a non-GAAP basis, adjusted net loss for 2025 was $16.0 million, improving from $19.3 million in 2024 as operating expenses fell, especially research and development. Cash, cash equivalents and restricted cash rose to $82.4 million at December 31, 2025 from $21.5 million a year earlier, mainly from an October 2025 private placement.
That financing delivered $80.0 million in gross proceeds and included Tranche A and Tranche B warrants that could provide up to an additional $120.0 million if fully exercised. The company plans to initiate a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia in Q2 2026, with topline data expected in 2H 2027.
Minerva Neurosciences discloses a 9.99% beneficial ownership position by Coastlands entities. The reporting persons state ownership of 4,563,031 shares, based on 43,274,398 shares outstanding as of December 23, 2025. The total consists of 2,159,245 shares held and 2,403,786 shares issuable upon conversion of Series A Convertible Preferred Stock and exercise of related warrants, with a stated beneficial ownership limitation of 9.99%.
The filing clarifies shared voting and dispositive power of 4,563,031 shares across Coastlands Capital LP, related entities, and Matthew D. Perry, and disclaims group membership and additional beneficial ownership beyond the 9.99% limitation.
Minerva Neurosciences, Inc. received a Schedule 13G from Logos Global Management and related entities reporting significant passive ownership of its common stock. Logos Global and several affiliated funds and managers together report beneficial ownership positions up to 4,435,444 shares, or 9.9% of Minerva’s common stock.
The holdings include a mix of common shares and Tranche A warrants for Series A preferred stock that is convertible into additional common shares, subject to a 9.99% voting securities cap that limits conversions above that level. The filing states the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control. Ownership percentages are calculated against 43,274,398 common shares outstanding as of December 23, 2025.